{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.5","upperLimit":"52.2","value":"46.8"},{"groupId":"OG001","lowerLimit":"40.1","upperLimit":"50.8","value":"45.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"331"},{"groupId":"OG001","value":"330"}],"units":"Participants"}],"description":"CBR was the best confirmed overall tumor response of stable disease (SD) for greater than or equal to (≥) 24 weeks, CR or PR as defined by RECIST v1.1. CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. SD is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD) for target lesions, no progression of non-target lesions, and no appearance of new lesions. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Imlunestrant 400 milligrams (mg) orally once daily on days 1 to 28 of a 28-day cycle, until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Arm A: Imlunestrant"},{"description":"Participants received the investigator's choice of endocrine therapy, either exemestane 25 mg administered orally once daily on days 1 to 28 of a 28-day cycle, or Fulvestrant 500 mg intramuscularly on days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond, until disease progression or a criterion for discontinuation was met.","id":"OG001","title":"Arm B: Investigator's Choice of Endocrine Therapy"}],"paramType":"NUMBER","populationDescription":"All participants who were randomly assigned to either arm A or arm B.","reportingStatus":"POSTED","timeFrame":"Randomization until measured progressive disease (up to 28 months)","title":"Percentage of Participants With Investigator-assessed Clinical Benefit Rate (CBR) (Between Arm A and Arm B)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}